Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPT-001
- Development stage
- Unknown
- Lead developer
- Atai Beckley
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
BPT-001 is a synthetic, intranasal formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a potent psychedelic compound being developed by Beckley Psytech. It acts primarily as a high-affinity agonist at the 5-HT2A and 5-HT1A serotonin receptors. Unlike other psychedelics such as psilocybin, 5-MeO-DMT is characterized by a rapid onset and a significantly shorter duration of psychedelic experience, typically lasting between 15 to 45 minutes. This short duration is intended to reduce the clinical resource burden and improve patient throughput in a therapeutic setting. Beckley Psytech is currently evaluating BPT-001 in Phase 2 clinical trials for the treatment of Treatment-Resistant Depression (TRD) and Alcohol Use Disorder (AUD), where it is administered in combination with psychological support to facilitate rapid and sustained therapeutic outcomes.
- Other names
- 5-MeO-DMT5-methoxy-N,N-dimethyltryptamine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on BPT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPT-001.